Advocacy
November 18, 2021, APNA signed onto a letter to the FDA expressing concerns about the implementation of the New Clozapine REMS (NCR).
November 18, 2021, APNA signed onto a letter to the FDA expressing concerns about the implementation of the New Clozapine REMS (NCR).
Connect with fellow psychiatric-mental health nurses, be the first to know about evidence-based resources and programs, and participate in exclusive opportunities to advance the care and treatment of those with mental health & substance use needs.
